What is HC Wainwright’s Estimate for ELDN Q1 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Eledon Pharmaceuticals in a research report issued on Wednesday, June 18th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.20.

Separately, Wall Street Zen cut shares of Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 6th.

Eledon Pharmaceuticals Trading Down 1.1%

ELDN opened at $2.78 on Thursday. The stock has a market capitalization of $166.47 million, a P/E ratio of -1.32 and a beta of -0.17. Eledon Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $5.54. The firm’s fifty day simple moving average is $3.04 and its 200 day simple moving average is $3.71.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. RA Capital Management L.P. acquired a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $14,693,000. First Light Asset Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $9,595,000. Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $8,075,000. Sphera Funds Management LTD. grew its position in Eledon Pharmaceuticals by 96.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock worth $10,513,000 after buying an additional 1,254,298 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Eledon Pharmaceuticals during the fourth quarter worth approximately $4,848,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).